Last reviewed · How we verify
Placebo for Ubrogepant
Placebo for Ubrogepant is a Small molecule drug developed by AbbVie. It is currently in Phase 3 development for Control arm in Phase 3 clinical trials for ubrogepant (acute migraine treatment).
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in Phase 3 clinical trials for ubrogepant (acute migraine treatment).
At a glance
| Generic name | Placebo for Ubrogepant |
|---|---|
| Sponsor | AbbVie |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (ubrogepant) by comparison. Any observed effects in the placebo group are attributed to natural disease progression, regression to the mean, or the placebo effect itself. This allows researchers to isolate the true therapeutic benefit of ubrogepant.
Approved indications
- Control arm in Phase 3 clinical trials for ubrogepant (acute migraine treatment)
Common side effects
Key clinical trials
- Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) (PHASE3)
- Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine (PHASE3)
- A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine (PHASE1)
- Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants (PHASE3)
- An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine (PHASE3)
- Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine (PHASE3)
- A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006) (PHASE2)
- Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Ubrogepant CI brief — competitive landscape report
- Placebo for Ubrogepant updates RSS · CI watch RSS
- AbbVie portfolio CI
Frequently asked questions about Placebo for Ubrogepant
What is Placebo for Ubrogepant?
How does Placebo for Ubrogepant work?
What is Placebo for Ubrogepant used for?
Who makes Placebo for Ubrogepant?
What development phase is Placebo for Ubrogepant in?
Related
- Manufacturer: AbbVie — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Control arm in Phase 3 clinical trials for ubrogepant (acute migraine treatment)
- Compare: Placebo for Ubrogepant vs similar drugs
- Pricing: Placebo for Ubrogepant cost, discount & access